Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?

Table 1 Clinicopathological features of patients with both Xp11.2 translocation RCC and ccRCC

Characteristics	Xp11.2 translocation RCC	ccRCC	P-value
Characteristics	No. (%)	No. (%)	P-value
Age			< 0.001
< 45	28 (82.4)	14 (18.2)
≥ 45	6 (17.6)	63 (81.8)
Gender			< 0.001
Male	13 (38.2)	58 (75.3)
Female	21 (61.8)	19 (24.7)
Laterality			0.093
Right	20 (58.8)	32 (41.6)
Left	14 (41.2)	45 (58.4)
Pathological T stage			0.654
pT1/pT2	29 (85.3)	63 (81.8)
pT3/pT4	5 (14.7)	14 (18.2)
Pathological N stage			0.251
pN₀	27 (79.4)	69 (89.6)
pN₁	7 (20.6)	8 (10.4)
Clinical M stage			0.999
cM₀	32 (94.1)	71 (92.2)
cM₁	2 (5.9)	6 (7.8)
AJCC stage			0.982
I/II	27 (79.4)	61 (79.2)
III/IV	7 (20.6)	16 (20.8)
WHO/ISUP grade			0.401
1/2	24 (70.6)	48 (62.3)
3/4	10 (29.4)	29 (37.7)
Tumor size (cm)	5.5 ± 2.7	5.6 ± 2.3	0.806

Xp11.2 translocation RCC Xp11.2 translocation renal cell carcinoma, ccRCC Clear cell renal cell carcinoma, AJCC American Joint Committee On Cancer, WHO/ISUP World Health Organization/International Society of Urological Pathology

ISSN: 1471-2407